We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

76 hedge funds and large institutions have $88.1M invested in Aevi Genomic Medicine Inc in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,853% more call options, than puts

Call options by funds: $6.58M | Put options by funds: $337K

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

12% more funds holding

Funds holding: 68 → 76 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $91.2M → $88.1M (-$3.13M)

Holders
76
Holders Change
+8
Holders Change %
+11.76%
% of All Funds
1.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
25
Reduced
15
Closed
6
Calls
$6.58M
Puts
$337K
Net Calls
+$6.24M
Net Calls Change
+$5.86M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.91M
2
BFA
BlackRock Fund Advisors
California
+$745K
3
Morgan Stanley
Morgan Stanley
New York
+$390K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$386K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$362K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.58M
2
QF
QVT Financial
New York
-$688K
3
SS
Sunbelt Securities
Texas
-$223K
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$203K
5
BFM
Boothbay Fund Management
New York
-$84K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$17.5M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$10.9M – – –
Jennison Associates
3
Jennison Associates
New York
$8.91M +$26.2K +4,988 +0.3%
OM
4
Opaleye Management
Massachusetts
$7.77M -$1.58M -300,000 -17%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.99M +$386K +73,452 +7%
BFA
6
BlackRock Fund Advisors
California
$4.59M +$745K +141,641 +19%
BBA
7
Baker Bros. Advisors
New York
$4.56M – – –
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$3.94M -$19.5K -3,700 -0.5%
BIT
9
BlackRock Institutional Trust
California
$3.36M -$16.7K -3,180 -0.5%
SFM
10
Sphera Funds Management
Israel
$2.33M – – –
CC
11
Casdin Capital
New York
$1.94M – – –
Millennium Management
12
Millennium Management
New York
$1.88M +$1.91M +362,700 New
State Street
13
State Street
Massachusetts
$1.79M +$243K +46,149 +15%
Northern Trust
14
Northern Trust
Illinois
$1.55M +$118K +22,358 +8%
PA
15
Perceptive Advisors
New York
$1.52M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.09M +$50.1K +9,517 +5%
BCM
17
Bridgeway Capital Management
Texas
$971K – – –
SM
18
Sabby Management
Florida
$716K -$19.9K -3,782 -3%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$583K +$18.9K +3,589 +3%
BIM
20
BlackRock Investment Management
Delaware
$500K -$9.76K -1,854 -2%
Morgan Stanley
21
Morgan Stanley
New York
$440K +$390K +74,113 +689%
TCIM
22
TIAA CREF Investment Management
New York
$434K +$14.3K +2,727 +3%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$357K +$362K +68,836 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$290K -$8.42K -1,600 -3%
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$264K – – –
1
2 3 4

GNMX Hedge Fund Activity: Q4 2016 in Review

76 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2016, worth a combined $88.1M — down 3.4% from $91.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GNMX positions and 6 closed out — a net gain of 8 holders — while 25 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.91M. The largest seller was Opaleye Management, cutting an estimated $1.58M.

  • 76 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2016, up from 68 in Q3 2016.
  • Funds reported $88.1M of Aevi Genomic Medicine Inc stock for Q4 2016, down 3.4% quarter-over-quarter.
  • 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2016 and 6 closed out, a net change of +8 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2016 was Millennium Management, an estimated $1.91M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2016 was Opaleye Management, an estimated $1.58M sold.

Based on aggregated 13F filings for Q4 2016.